Temozolomide Dosing Regimens for Glioma Patients

[1]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[2]  F. Ducray,et al.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Marosi,et al.  Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Aldape,et al.  RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Sommer,et al.  MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma , 2010, International journal of cancer.

[6]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Kretzschmar,et al.  Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  M. Gilbert,et al.  A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma , 2010, Neuro-Oncology.

[9]  K. Kallenberg,et al.  Near-continuous temozolomide and low-dose weekly CCNU: A novel chemotherapy regimen with activity in malignant gliomas resistant to dose-dense temozolomide alone. , 2010 .

[10]  T. Tominaga,et al.  O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma , 2010, International Journal of Clinical Oncology.

[11]  B. Kaina,et al.  Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles , 2010, Cell cycle.

[12]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Balañà,et al.  Extended-schedule dose-dense temozolomide in refractory gliomas , 2009, Journal of Neuro-Oncology.

[14]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[15]  J. Uhm.  Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule: The “Rescue” Approach , 2009 .

[16]  M. Christmann,et al.  Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. , 2008, Molecular medicine reports.

[17]  R. Soffietti,et al.  Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: A phase II AINO study , 2008 .

[18]  A. Brandes,et al.  Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas , 2008, Journal of Neuro-Oncology.

[19]  J. Menten,et al.  A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma , 2008, Cancer investigation.

[20]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[21]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Weller,et al.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine , 2007, Oncogene.

[23]  N. Pouratian,et al.  Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas , 2007, Journal of Neuro-Oncology.

[24]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[25]  C. Sommer,et al.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[27]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[28]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[29]  R. Grobholz,et al.  Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme , 2004, Journal of Cancer Research and Clinical Oncology.

[30]  M. Weller,et al.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[32]  M. Christmann,et al.  DNA repair in resistance to alkylating anticancer drugs. , 2002, International journal of clinical pharmacology and therapeutics.

[33]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[34]  M. member.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[35]  H. Eyre,et al.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Kaina,et al.  Protective effect of O6‐methylguanine‐DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs , 1996, International journal of cancer.

[37]  R. Benjamin,et al.  A Phase I trial of weekly lomustine in patients with advanced cancer , 1994, Cancer.

[38]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[39]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.